Waters Corporation
Waters Corporation (NYSE: WAT) designs, manufactures, sells and services analytical instruments, software, consumables and support plans used in laboratory research, quality control and testing. Its core products include high- and ultra-performance liquid chromatography systems, mass spectrometry instruments and… From the company’s description.
In fiscal 2025, Waters Corporation reported revenue of $3.17B, up 7.0% from fiscal 2024, and net income of $642.63M. Its operating margin was 25.4%, and operations generated $652.55M in cash. Over the twelve months to Jul 4, 2026, revenue was $4.64B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Waters Corporation does
In the company’s own words
Waters Corporation (NYSE: WAT) designs, manufactures, sells and services analytical instruments, software, consumables and support plans used in laboratory research, quality control and testing. Its core products include high- and ultra-performance liquid chromatography systems, mass spectrometry instruments and chromatography columns; its TA Instruments line provides thermal analysis, rheometry and calorimetry equipment. Customers include pharmaceutical and biotechnology companies, clinical and contract research laboratories, industrial firms, food and beverage companies, universities and government agencies. In 2025, pharmaceutical accounts generated 59% of net sales, other industrial customers 30%, and academic and government customers 11%. Before its February 2026 acquisition of BD’s Biosciences and Diagnostic Solutions businesses, Waters and TA were its operating segments, aggregated as one reporting segment. Following the acquisition, the company reorganized its businesses into Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics and Waters Materials Sciences. The acquisition added specimen collection products, diagnostic instruments and reagents, flow cytometry and multiomics tools. Waters employed approximately 7,900 people at year-end 2025. Its website is www.waters.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Medical Instruments
- Headquarters
- MILFORD, MA
- Fiscal year end
- December
- CIK
- 1000697
- SIC
- 3826
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Waters Corporation — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Waters Corporation · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Waters Corporation’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Waters Corporation and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Waters Corporation's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Waters Corporation's last four quarterly filings that the numbers alone won't show?”